Key result
Terazosin binds PGK1 and attenuates vascular senescence in preclinical models.
Why the study?
It remains unclear whether terazosin modifies aging-related biology directly or mainly protects against specific injuries and diseases, and whether its effects depend on phosphoglycerate kinase 1.
Does terazosin modify aging-related biology and improve vascular and cellular maintenance through phosphoglycerate kinase 1 (PGK1) engagement, or does it mainly protect against specific disease insults?
Does terazosin modify aging-related biology and improve vascular and cellular maintenance through phosphoglycerate kinase 1 (PGK1) engagement, or does it mainly protect against specific disease insults?
Answers are grounded in this paper and cite their sources.
This review demonstrates that while terazosin engages PGK1 to protect against acute cellular stress and improves endothelial senescence and arterial function in aged mice, randomized blood-pressure-matched human trials are needed to confirm whether tolerated clinical doses engage vascular PGK1 to modify human vascular aging.
Does terazosin (TZ) modify aging-related biology, or does it mainly protect against particular injuries and diseases? This review examines what TZ changes, whether the response depends on phosphoglycerate kinase 1 (PGK1), and whether an aging-associated state and tissue function were measured together. TZ binds PGK1 directly and alters its catalytic activity. PGK1 perturbation changes the protective response to TZ in selected stress models. The strongest evidence for an effect on aging-related biology comes from vascular studies. TZ attenuated the development of senescence-associated changes in cultured endothelial cells and improved endothelium-dependent dilation in naturally aged mice. Other models show protection against neurodegeneration, metabolic stress or acute injury. Their metabolic responses vary, from increased brain adenosine triphosphate (ATP) in parkinsonian models to improved endothelial redox control with no detectable change in bulk respiration or extracellular acidification. In humans, oral TZ reaches cerebrospinal fluid and can alter whole-blood ATP. Arterial stiffness and blood pressure fell together in an observational study. Human vascular PGK1 engagement and an effect on the aging process remain open questions. A randomized blood-pressure-matched study in older adults with arterial stiffness and an existing indication for α1 blockade could test whether tolerated exposure engages vascular PGK1 and improves function.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in Age-related diseases and vascular aging. Terazosin was evaluated. Terazosin binds phosphoglycerate kinase 1 and attenuates vascular senescence in cells and aged mice, though human vascular PGK1 engagement remains unestablished.
Synapse has enriched 10 related papers. Consider them for comparative context: